Comparative Pharmacology
Head-to-head clinical analysis: GLEOSTINE versus NEOSAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLEOSTINE versus NEOSAR.
GLEOSTINE vs NEOSAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GLEOSTINE (lomustine) is a nitrosourea alkylating agent that crosslinks DNA and RNA, inhibiting DNA synthesis and repair. It is cell cycle phase-nonspecific.
Alkylating agent that inhibits DNA replication and transcription by cross-linking DNA strands, leading to cell cycle arrest and apoptosis.
130 mg/m2 orally every 6 weeks as a single dose; alternatively, 75 mg/m2 orally every 3 weeks.
Cyclophosphamide 500-1500 mg/m² IV every 2-4 weeks; oral 50-200 mg daily.
None Documented
None Documented
16-48 hours (terminal), with an active metabolite half-life of up to 5 days, requiring dose adjustment for renal impairment
Terminal elimination half-life: 3-5 hours; prolonged in hepatic impairment (up to 12 hours).
Renal: 60% (as metabolites), Fecal: <5% (unchanged and metabolites), Biliary: minimal
Renal: 30-60% unchanged; biliary/fecal: 10-20% as metabolites.
Category C
Category C
Alkylating Agent
Alkylating Agent